Walleye Capital’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-79,666
| Closed | -$1.6M | – | 4960 |
|
|
2026
Q1 | $1.6M | Buy |
+79,666
| New | +$1.28M | 0.01% | 1649 |
|
|
2025
Q2 | – | Sell |
-249,161
| Closed | -$3.05M | – | 4785 |
|
|
2025
Q1 | $2.88M | Sell |
249,161
-18,582
| -7% | -$190K | 0.01% | 1176 |
|
|
2024
Q4 | $2.27M | Buy |
+267,743
| New | +$2.77M | 0.01% | 1671 |
|
|
2024
Q2 | – | Sell |
-120,308
| Closed | -$1.43M | – | 5793 |
|
|
2024
Q1 | $1.43M | Buy |
120,308
+22,478
| +23% | +$300K | ﹤0.01% | 2249 |
|
|
2023
Q4 | $1.2M | Buy |
97,830
+39,452
| +68% | +$359K | ﹤0.01% | 2210 |
|
|
2023
Q3 | $562K | Buy |
+58,378
| New | +$596K | ﹤0.01% | 2721 |
|
|
2023
Q1 | – | Sell |
-32,482
| Closed | -$220K | – | 4159 |
|
|
2022
Q4 | $220K | Sell |
32,482
-116,385
| -78% | -$623K | ﹤0.01% | 1976 |
|
|
2022
Q3 | $2.16M | Sell |
148,867
-55,471
| -27% | -$775K | 0.04% | 518 |
|
|
2022
Q2 | $2.01M | Buy |
204,338
+140,128
| +218% | +$1.55M | 0.06% | 365 |
|
|
2022
Q1 | $946K | Buy |
+64,210
| New | +$923K | 0.03% | 665 |
|
|
2020
Q3 | – | Sell |
-16,676
| Closed | -$202K | – | 906 |
|
|
2020
Q2 | $202K | Sell |
16,676
-4,124
| -20% | -$43.9K | 0.05% | 433 |
|
|
2020
Q1 | $159K | Buy |
+20,800
| New | +$281K | 0.04% | 492 |
|
Other funds holding KALV
Walleye Capital's KALV Position: Q2 2026 in Review
Walleye Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 79,666 shares — an estimated $1.6M sold.
Walleye Capital first reported a position in KALV in Q1 2020 and held it in 12 quarters. The position peaked at $2.88M in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Walleye Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Capital sold 79,666 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
- Walleye Capital first reported a position in KalVista Pharmaceuticals in Q1 2020 and held it in 12 quarters.
- Walleye Capital's KalVista Pharmaceuticals position peaked at $2.88M in Q1 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.